Telix Pharmaceuticals Ltd
ASX:TLX

Watchlist Manager
Telix Pharmaceuticals Ltd Logo
Telix Pharmaceuticals Ltd
ASX:TLX
Watchlist
Price: 24.78 AUD -3.39% Market Closed
Market Cap: 8.4B AUD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one TLX stock under the Base Case scenario is 30.81 AUD. Compared to the current market price of 24.78 AUD, Telix Pharmaceuticals Ltd is Undervalued by 20%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

TLX Relative Value
Base Case
30.81 AUD
Undervaluation 20%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

10.6
P/S
P/S
Price to Sales
10.6
vs History
71
vs Industry
39
Median 3Y
11.3
Median 5Y
20.7
Industry
7.2
Forward
6.4
More Details
166.2
P/E
P/E
Price to Earnings
166.2
vs History
19
vs Industry
1
Median 3Y
-12.2
Median 5Y
-18.4
Industry
23.2
Forward
45.4
More Details
192.8
P/OCF
P/OCF
Price to OCF
192.8
vs History
30
vs Industry
1
Median 3Y
144.2
Median 5Y
-12.4
Industry
19.3
More Details
12.7
P/FCFE
P/FCFE
Price to FCFE
12.7
vs History
46
vs Industry
10
Median 3Y
14.6
Median 5Y
-11.9
Industry
22.5
More Details
14.6
P/B
P/B
Price to Book Value
14.6
vs History
76
vs Industry
5
Median 3Y
22
Median 5Y
21.1
Industry
2.7
More Details
10.4
EV/S
EV/S
Enterprise Value to Sales
10.4
vs History
71
vs Industry
33
Median 3Y
11.1
Median 5Y
20
Industry
7.5
Forward
6.3
More Details
16.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
16.8
vs History
71
vs Industry
26
Median 3Y
17.9
Median 5Y
33.7
Industry
9.4
More Details
101.9
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
101.9
vs History
19
vs Industry
1
Median 3Y
-11.5
Median 5Y
-18.1
Industry
4.6
Forward
40.8
More Details
101.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
101.9
vs History
19
vs Industry
1
Median 3Y
-11.5
Median 5Y
-18.1
Industry
4.5
Forward
35.5
More Details
189.3
EV/OCF
EV/OCF
Enterprise Value to OCF
189.3
vs History
30
vs Industry
1
Median 3Y
142.2
Median 5Y
-11.5
Industry
4.9
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
0
Median 3Y
-13.4
Median 5Y
-17.1
Industry
3.7
More Details
11
EV/IC
EV/IC
Enterprise Value to IC
11
vs History
80
vs Industry
16
Median 3Y
16.4
Median 5Y
16.1
Industry
4.9
More Details

Multiples Across Competitors

TLX Competitors Multiples
Telix Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Telix Pharmaceuticals Ltd
ASX:TLX
8.3B AUD 10.6 166.2 101.9 101.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 202 723.3 -162 560.5 -197 400.3 -195 147.7
US
Abbvie Inc
NYSE:ABBV
337.5B USD 5.9 81.2 15.4 22.8
US
Amgen Inc
NASDAQ:AMGN
158.7B USD 4.7 26.8 14.4 23.7
US
Gilead Sciences Inc
NASDAQ:GILD
136.9B USD 4.8 23 10 13.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117B USD 10.5 -118.3 25.2 26.4
US
Epizyme Inc
F:EPE
94.1B EUR 2 059.8 -525.6 -572.3 -557.1
AU
CSL Ltd
ASX:CSL
115.7B AUD 4.9 27.3 16.9 21.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
57.3B USD 4.1 12.7 11.3 12.7
US
Seagen Inc
F:SGT
39.3B EUR 19.8 -60.8 -65.6 -59.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
40.1B USD 17.1 -148.8 -666.4 -333.9
P/S Multiple
Revenue Growth P/S to Growth
AU
Telix Pharmaceuticals Ltd
ASX:TLX
Average P/S: 3 109 533.2
10.6
35%
0.3
FR
Pharnext SCA
OTC:PNEXF
34 202 723.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.9
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.5
10%
1.1
US
E
Epizyme Inc
F:EPE
2 059.8
N/A N/A
AU
CSL Ltd
ASX:CSL
4.9
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.1
4%
1
US
S
Seagen Inc
F:SGT
19.8
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
17.1
29%
0.6
P/E Multiple
Earnings Growth PEG
AU
Telix Pharmaceuticals Ltd
ASX:TLX
Average P/E: 56.2
166.2
97%
1.7
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 560.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
81.2
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.8
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -118.3 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -525.6 N/A N/A
AU
CSL Ltd
ASX:CSL
27.3
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.7
7%
1.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -148.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Telix Pharmaceuticals Ltd
ASX:TLX
Average EV/EBITDA: 27.9
101.9
79%
1.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 400.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -572.3 N/A N/A
AU
CSL Ltd
ASX:CSL
16.9
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.3
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -666.4 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Telix Pharmaceuticals Ltd
ASX:TLX
Average EV/EBIT: 31.8
101.9
88%
1.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 147.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.8
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.7
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.8
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.4
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -557.1 N/A N/A
AU
CSL Ltd
ASX:CSL
21.1
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.7
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -333.9 N/A N/A

See Also

Summary
TLX intrinsic value, competitors valuation, and company profile.
DCF Valuation
TLX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
TLX stock valuation using valuation multiples.
Wall Street Estimates
TLX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
TLX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 261,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.